Welcome to our dedicated page for Applied Genetic news (Ticker: AGTC), a resource for investors and traders seeking the latest updates and insights on Applied Genetic stock.
The AGTC (Applied Genetic Technologies Corporation) news archive on Stock Titan covers the company’s history as a clinical-stage biotechnology developer of adeno-associated virus (AAV)-based gene therapies for rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. News releases repeatedly describe AGTC’s focus on inherited retinal diseases, with its most advanced clinical programs in X-linked retinitis pigmentosa (XLRP) and achromatopsia due to CNGB3 variants (ACHM CNGB3).
Readers will find detailed coverage of the strategic transaction in which a portfolio company of Syncona Limited agreed to acquire AGTC through a tender offer and subsequent merger. Multiple releases from October through December 2022 outline the tender offer terms, the board’s unanimous recommendation, reminders to shareholders about tender deadlines, and the final confirmation that the acquisition closed and AGTC became an indirect, wholly owned subsidiary of Syncona Limited, with its common stock delisted from the Nasdaq Global Stock Market.
The archive also includes earlier corporate updates, such as announcements about AGTC’s participation in investor conferences and reiterations of its development strategy in AAV-based gene therapy, inherited retinal disease programs, and preclinical work in optogenetics, otology and CNS disorders. In addition, later news from Beacon Therapeutics references laru-zova (laruparetigene zovaparvovec), described in a presentation title as “AGTC-501,” providing continuity for those tracking the historical XLRP program originally developed at AGTC.
Investors, researchers and industry observers can use this news page to review AGTC’s public communications, understand the rationale and structure of the Syncona acquisition, and follow how AGTC’s legacy XLRP asset is referenced in subsequent clinical trial updates from Beacon Therapeutics.
Applied Genetic Technologies Corporation (AGTC), a biotechnology firm focused on gene therapies for rare diseases, announced that CEO Sue Washer will present at the BMO Capital Markets 2020 Healthcare Conference on June 23 at 10:30 am ET. The event can be streamed live on the company's website, with a replay available afterward. Earlier this year, AGTC reported promising interim data from its clinical trials for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) therapies, demonstrating the company's commitment to addressing significant unmet medical needs.
Applied Genetic Technologies Corporation (AGTC) published positive preclinical data supporting its AAV-based gene therapy for X-linked Retinitis Pigmentosa (XLRP). The study, conducted in a canine model, showed that AGTC's proprietary AAV vectors effectively corrected early disease markers and exhibited a favorable safety profile. These findings provide a foundation for the ongoing Phase 1/2 clinical trial of its product candidate.
The data also led to the selection of rAAV2tYF-GRK1-hRPGRco as the optimized vector for advancing clinical trials.
Applied Genetic Technologies Corporation (AGTC) reported financial results for Q3 2020, revealing total revenue of $2.5 million, a decline from $41.3 million in Q3 2019. The net loss was $11.2 million. AGTC remains optimistic about ongoing clinical programs for XLRP and ACHM, with multiple data readouts expected in the second half of 2020. The company reported minimal impact from COVID-19 and successfully completed enrollment in key clinical trials. As of March 31, 2020, cash reserves stand at $84.5 million, projected to fund operations into 2021.
Applied Genetic Technologies Corporation (AGTC) will report its financial results for the fiscal quarter ending March 31, 2020, on May 13, 2020, before market opening. A conference call is scheduled for 8:00 AM ET on the same day to review the results and provide updates. AGTC is focused on gene therapies for rare diseases, with ongoing clinical trials in ophthalmology including conditions like X-linked retinitis pigmentosa and achromatopsia. The company also has preclinical programs targeting other serious diseases.